Opinion|Videos|September 10, 2024
Managing toxicities of BCMA_targeting Bispecfics
Author(s)Larysa Sanchez, MD, Samantha Shenoy, NP, MSN
Experts explore additional toxicities observed with B-cell maturation antigen–targeting bispecifics, such as infections, neurotoxicity, and hematological issues, and discuss how these are managed in practice.
Advertisement
Episodes in this series
Video content above is prompted by the following:
What are some other toxicities observed with B-cell maturation antigen–targeting bispecifics? How are they managed in your practice?
- Infections, neurotoxicity, hematological toxicities
Advertisement
Related to this article
![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
2
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
3
Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery
4
FDA OKs Pirtobrutinib in Frontline CLL/SLL
5